Does Cigna Cover Jardiance (Empagliflozin)?

What Is Jardiance and Why Does Coverage Matter?

Jardiance is the brand name for empagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for three separate clinical indications. The drug's mechanism is straightforward: it blocks glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in the urine. That action produces modest A1C reduction (roughly 0.6, 0.8 percentage points at 10 mg), but the cardiovascular and renal benefits observed in large outcomes trials go well beyond glycemic control.

The FDA has approved empagliflozin 10 mg and 25 mg for glycemic control in type 2 diabetes, for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure with reduced ejection fraction (HFrEF) and, more recently, heart failure with preserved ejection fraction (HFpEF), and for slowing progression of chronic kidney disease (CKD) in adults at risk of progression. [1]

Coverage matters because the list price of Jardiance sits at approximately $680 per month, a figure that is effectively out of reach for most patients without insurance support. A Cigna approval (or denial) can mean the difference between a patient receiving a drug with proven mortality benefit and that patient going without it.

Is Jardiance on the Cigna Formulary?

Jardiance appears on most Cigna commercial formularies as a covered brand-name drug, generally placed at Tier 3 (preferred brand). Tier 3 means a higher co-pay than generic drugs (Tier 1) or preferred generics (Tier 2), but a lower out-of-pocket cost than Tier 4 or Tier 5 non-preferred or specialty agents.

Cigna operates numerous plan designs: Open Access Plus (OAP), LocalPlus, Choice Fund, and employer-sponsored self-funded plans. The formulary can differ across these designs even within the same geographic region. A patient on a Cigna OAP employer plan and a colleague on a Cigna LocalPlus plan in the same office may face different co-pays and different PA criteria for the exact same drug.

The practical implication: always verify your specific plan's formulary at the time of prescribing by calling the member services number on the back of your insurance card or by using Cigna's online drug-search tool. Your pharmacist can also run a real-time eligibility check before you submit the prescription.

Cigna's national pharmacy and therapeutics (P&T) committee reviews SGLT2 inhibitors as a class. Because generic empagliflozin became available in the United States in late 2023, Cigna and other payers have begun in some cases repositioning the branded product relative to the generic on their formularies. As of the date of this article's last review, branded Jardiance remains Tier 3 on most Cigna commercial plans, while generic empagliflozin may sit at Tier 2 on plans that have added it. [2]

Cigna Prior Authorization Criteria for Jardiance

Prior authorization (PA) is required on essentially all Cigna commercial plans. PA for Jardiance is rated "moderate difficulty" by independent insurance analysis firms, meaning approval is generally achievable with complete documentation but is not automatic. [3]

The specific criteria Cigna applies vary by indication.

Type 2 Diabetes Indication

For the glycemic indication, Cigna's PA criteria typically require all of the following:

• A confirmed diagnosis of type 2 diabetes (not type 1)
• A documented A1C, usually above 7.0%, within the preceding 6 months
• Evidence that the patient has tried or has a documented contraindication to metformin at an adequate dose (step therapy; see below)
• A prescriber who is either a primary care physician, endocrinologist, or cardiologist managing the patient's metabolic care

Heart Failure Indication

For the heart failure indication (both HFrEF and HFpEF), PA criteria typically require:

• An echocardiogram or imaging report confirming left ventricular ejection fraction (LVEF) with the relevant classification
• A diagnosis of New York Heart Association (NYHA) Class II or III heart failure
• Concurrent use of, or documented contraindication to, other guideline-directed medical therapy (GDMT), including a beta-blocker and either an ACE inhibitor, ARB, or ARNI where tolerated
• A cardiologist or heart failure specialist as the prescribing or co-signing clinician on some plan variants

Chronic Kidney Disease Indication

For CKD, Cigna typically requires:

• An eGFR result (generally in the range of 20 to 45 mL/min/1.73m² for the CKD progression indication) documented within 6 months
• A urine albumin-to-creatinine ratio (UACR) above 200 mg/g in most cases
• Nephrology or primary care documentation confirming the CKD stage and cause

Your prescriber should submit the PA package with all supporting laboratory values, visit notes, and the clinical rationale. Incomplete submissions are the single most common reason for initial PA delays rather than outright denials.

Step Therapy Requirements for Jardiance on Cigna

Step therapy is common for the type 2 diabetes indication. Cigna, like most commercial payers, considers metformin the first-line oral agent for T2D in alignment with the American Diabetes Association's 2024 Standards of Care, which state: "Metformin remains the preferred initial glucose-lowering medication for type 2 diabetes management due to its efficacy, safety, and low cost." [4]

In practice, Cigna's step therapy requirement for Jardiance in diabetes usually means the patient must have a documented 90-day trial of metformin (at the maximally tolerated dose) unless one of the following exceptions applies:

• Metformin is contraindicated (eGFR <30 mL/min/1.73m² or active hepatic disease)
• The patient had a documented intolerance (gastrointestinal adverse effects despite extended-release formulation at adequate dose)
• The patient's cardiovascular or renal risk profile makes early SGLT2 inhibitor therapy a guideline-supported priority

That last exception is where clinical nuance matters most. The 2023 ACC/AHA Heart Failure Guidelines and the 2022 ADA/EASD Consensus Report both support early use of SGLT2 inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD) or CKD regardless of A1C or metformin history. [5] A prescriber who documents this rationale explicitly in the PA request may bypass step therapy entirely.

Step therapy does not apply to the heart failure or CKD indications under most current Cigna PA policies.

The Evidence Cigna Reviewers Are Reading

Insurance medical directors reviewing Jardiance PAs look at the same outcomes trials that informed FDA approval and major cardiology and nephrology guidelines.

The EMPA-REG OUTCOME trial (N=7,020, published in NEJM 2015) randomized adults with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg, 25 mg, or placebo. Empagliflozin produced a 14% relative reduction in 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke) versus placebo (10.5% vs. 12.1%; hazard ratio 0.86 to 95% CI 0.74, 0.99; P<0.001 for non-inferiority, P=0.04 for superiority). Cardiovascular death was reduced by 38% in the empagliflozin group. [6]

The EMPEROR-Reduced trial (N=3,730) demonstrated a 25% relative reduction in the composite of cardiovascular death or hospitalization for heart failure with empagliflozin 10 mg vs. placebo in patients with HFrEF. [7]

The EMPEROR-Preserved trial (N=5,988) extended the benefit to HFpEF, showing a 21% relative risk reduction in cardiovascular death or heart failure hospitalization. [8]

The EMPA-KIDNEY trial (N=6,609) enrolled adults with CKD and showed a 28% relative risk reduction in the primary composite of kidney disease progression or cardiovascular death with empagliflozin 10 mg vs. placebo. [9]

These are not small mechanistic studies. They are large, placebo-controlled, randomized trials with hard outcomes, and Cigna's PA reviewers are expected to weigh them. Prescribers who cite the specific trial by name and indicate the patient's qualifying characteristics (established ASCVD, LVEF below 40%, eGFR in the 20, 45 range) substantially strengthen the PA narrative.

How to Appeal a Cigna Denial of Jardiance

Cigna denials of Jardiance are not final. Federal law (under the ACA and ERISA for self-funded plans) guarantees members a structured appeal process. The pathway has two internal levels and one external level.

Level 1 Internal Appeal

File within 180 days of the denial notice for most commercial plans (60 days for some employer plans; check your specific Summary Plan Description). Submit the following with the appeal:

• A letter of medical necessity from the prescribing physician referencing the specific trial data and guideline language supporting use
• All laboratory values (A1C, eGFR, UACR, echocardiogram report as relevant)
• Documentation of why step-therapy alternatives have failed or are contraindicated
• Any peer-reviewed literature specific to the patient's indication

Cigna must respond to a Level 1 urgent appeal within 72 hours and a standard appeal within 30 days.

Level 2 Internal Appeal

If Level 1 is denied, request a Level 2 review. This review is conducted by a Cigna medical director who was not involved in the first decision. The same documentation applies; add any new clinical notes or updated labs.

External Independent Review Organization (IRO)

After both internal levels are exhausted, the member may request external review by an IRO. The IRO's decision is binding on Cigna. IRO reviewers are board-certified clinicians in the relevant specialty and are prohibited from any financial relationship with Cigna. External review overturn rates for specialty drugs with strong clinical evidence tend to be favorable. One analysis of state external review outcomes found that consumers won approximately 39 to 59% of external reviews depending on the state and drug class. [10]

The HealthRX appeals framework for Jardiance denials follows a "documentation ladder" approach: each appeal level adds one tier of new evidence that was not submitted at the previous level. Starting with the trial citation at Level 1, adding a specialist letter at Level 2, and reserving a peer-to-peer call request (Cigna does permit prescriber-to-medical-director peer-to-peer conversations before or after a denial) for the transition to external review creates a systematically stronger record.

What Happens When Cigna Denies for Off-Label Use: Weight Loss

Cigna does not cover Jardiance specifically for weight loss. Empagliflozin is not FDA-approved for obesity or weight management, and Cigna's PA criteria are tied to FDA-approved indications. The weight reduction seen with empagliflozin in clinical trials (roughly 2 to 3 kg vs. placebo in EMPA-REG OUTCOME) is considered a secondary metabolic benefit of an approved indication, not a standalone reason for coverage.

Patients seeking coverage for a weight-focused SGLT2 strategy should discuss whether they qualify for Jardiance under a cardiovascular or renal indication, or whether a GLP-1 receptor agonist (semaglutide, tirzepatide) approved specifically for chronic weight management is a more appropriate coverage pathway given their clinical profile.

Formulary Alternatives Cigna May Require or Prefer

Because empagliflozin is one of three SGLT2 inhibitors with outcomes data, Cigna may prefer one agent over another depending on plan-year formulary negotiations. The alternatives in the SGLT2 class include:

• Dapagliflozin (Farxiga): FDA-approved for T2D, HFrEF, HFpEF, and CKD; outcomes supported by DAPA-HF (N=4,744 to 26% relative risk reduction in worsening heart failure or CV death) [11] and DAPA-CKD (N=4,304 to 39% relative risk reduction in composite kidney or CV endpoint). [12]
• Canagliflozin (Invokana): FDA-approved for T2D and CKD; outcomes data from CREDENCE (N=4,401). Generic canagliflozin became available and may sit at a lower formulary tier. [13]

If Cigna's formulary places dapagliflozin at a lower tier than empagliflozin for a given plan year, the insurer may ask the prescriber to justify choosing Jardiance over the preferred agent. A clinician can document patient-specific factors (prior response, tolerability, specialist preference based on a specific trial population that matched the patient's characteristics) to support the choice.

Cost Reduction Options When Cigna Coverage Is Partial or Denied

Even with PA approval, Tier 3 co-pays on Cigna commercial plans typically range from $50 to $100 per 30-day supply depending on deductible status and plan design. Several options exist to reduce out-of-pocket cost.

Eli Lilly Patient Assistance and Co-Pay Card

Boehringer Ingelheim and Eli Lilly, the co-developers of Jardiance, offer the Jardiance Savings Card for eligible commercially insured patients. Commercially insured patients who are not enrolled in a federal program (Medicare, Medicaid, TRICARE) may pay as little as $10 per month, up to a defined annual maximum savings amount. The savings card cannot be used by Medicare or Medicaid beneficiaries. [14]

LillyAnswers / BI Cares Foundation

For uninsured or underinsured patients or those who do not qualify for the savings card, Eli Lilly's LillyAnswers program and the Boehringer Ingelheim Cares Foundation provide free or reduced-cost medication to qualifying low-income patients. Income and insurance status eligibility thresholds apply.

Generic Empagliflozin

Generic empagliflozin entered the U.S. market in late 2023 following patent litigation. At pharmacies using GoodRx or similar discount programs, generic empagliflozin 10 mg may be available for $150, $250 per month, substantially below the branded list price, though still above what an insured patient with co-pay card assistance would pay.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) listed generic empagliflozin at prices well below traditional pharmacy retail as of 2024. Patients who cannot obtain insurance coverage should check this platform, though inventory availability can vary.

Tips for Prescribers Submitting a Cigna PA for Jardiance

1. Use Cigna's electronic PA portal (CoverMyMeds or eviCore, depending on the plan) rather than fax. Electronic submission creates a timestamped record and typically accelerates processing.
2. Attach the specific echocardiogram report, the eGFR trend over 6 to 12 months, or the cardiovascular risk documentation. Cigna reviewers need to see the data, not just a summary.
3. Write "established ASCVD per ACC/AHA definition" or "NYHA Class II HFpEF per 2023 ACC/AHA guidelines" in the free-text rationale field rather than vague language like "heart disease."
4. Request an urgent/expedited PA review if the patient is hospitalized or has had a recent cardiac event. Cigna must respond to urgent requests within 72 hours.
5. Schedule a peer-to-peer call proactively. Cigna permits prescriber-to-medical-director calls, and these conversations resolve many borderline denials before a formal Level 1 appeal is necessary.

The ADA's 2024 Standards of Care in Diabetes note directly: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended independent of baseline A1C." [4] Quoting that sentence verbatim in a PA letter carries weight with a reviewing medical director.

Medicare and Medicaid Coverage of Jardiance Through Cigna Plans

Cigna administers Medicare Advantage (MA) plans in many markets. Jardiance coverage under Cigna Medicare Advantage differs from commercial coverage in several ways.

Under Medicare Part D (which governs drug coverage in both standalone PDPs and MA-PD plans), empagliflozin must appear on a plan's formulary to be covered. CMS requires all Part D formularies to include at least two SGLT2 inhibitors, so Jardiance or its generic is likely covered on most Cigna MA-PD plans. However, the tier placement and PA requirements may differ from commercial plans.

Medicare beneficiaries cannot use the Jardiance Savings Card or manufacturer co-pay assistance programs, which is a common source of patient confusion. The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket costs at $2,000 per year starting in 2025, which may significantly reduce the annual burden for Jardiance users on Medicare. [15]

For Cigna Medicaid managed care plans, formulary placement and PA criteria are set by individual state contracts. Some states have established preferred drug lists that place one SGLT2 inhibitor over another, and Medicaid programs are generally not eligible for manufacturer savings cards. Check with the state-specific Cigna Medicaid plan directly.